Marcus Furch, PhD, MBA

RBT_mf5With 15 years in the life science industry, Marcus Furch has secured considerable experience in Corporate M&A, Business Development & Strategic Planning including general management.

Today, he is a managing partner and CEO/CFO of the venture capital financed Rodos BioTarget GmbH. In this role, he plans and executes the corporate strategy, provides overarching leadership and direction to the team of internal and external stakeholders.

Prior to Rodos, Marcus has advised and co-founded several start-up companies rendering medical services or providing biotechnology products. In advisory and interim management assignments for clients in the healthcare industry, in the founding team of a M&A boutique, as well as in permanent management positions at Fresenius SA, he was involved in merger and acquisition, licensing, corporate financing and venturing, as well as trans-border transactions, both in established and emerging markets.

In positions of significant corporate influence at Fresenius, he contributed, for instance, to building a portfolio comprising stage I to stage III clinical trial projects. Prior to joining Fresenius, he was a management consultant in São Paulo providing services to enforce the competitiveness of chemical and pharmaceutical enterprises.

Before Marcus got involved in management and business economic assignments, he had worked for more than six years as Research Scientist in international and renowned laboratories in Germany (Max-Planck Society and Hannover Medical School), France (INSERM-CNRS), Spain (Universidad del Pais Vasco), and the US (The Scripps Research Institute). He received his advanced degree in chemistry and his PhD in biophysics and biochemistry from the University of Heidelberg. He also holds an executive MBA from the Business School of the Maastricht University (The Netherlands). Marcus is a native German and also speaks English, Spanish, Portuguese and French.